enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Dapagliflozin - Wikipedia

   en.wikipedia.org/wiki/Dapagliflozin

   Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [6] [7] [10] It is also used to treat adults with heart failure and chronic kidney disease.

3. AstraZeneca diabetes drug gets U.S. nod to treat heart failure

   www.aol.com/news/astrazenecas-diabetes-drug-gets...

   The U.S. Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular death and hospitalisation for heart failure in certain patients, regardless of their diabetes ...

4. AstraZeneca's Farxiga cuts death risk in heart failure ... - AOL

   www.aol.com/news/astrazenecas-farxiga-cuts-death...

   AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...

5. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

6. Management of heart failure - Wikipedia

   en.wikipedia.org/wiki/Management_of_heart_failure

   Sleep apnea is an under-recognized risk factor for heart failure. Uncontrolled sleep apnea may increase the risk of heart failure by up to 140%. [4] Weight reduction – through physical activity and dietary modification, as obesity is a risk factor for heart failure and left ventricular hypertrophy. Effective weight management has been shown ...

7. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...